Prelude Capital Management’s Cogent Biosciences COGT Stock Holding History

Prelude Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-64,222	Closed	-$2.47M	–	1279
2026 Q1	$2.47M	Sell	64,222 -8,156	-11%	-$301K	0.19%	128
2025 Q4	$2.57M	Sell	72,378 -64,903	-47%	-$1.82M	0.19%	116
2025 Q3	$1.97M	Sell	137,281 -25,900	-16%	-$307K	0.15%	167
2025 Q2	$1.17M	Sell	163,181 -6,268	-4%	-$34.7K	0.11%	226
2025 Q1	$1.01M	Buy	+169,449	New	+$1.33M	0.08%	306
2023 Q4	–	Sell	-27,100	Closed	-$264K	–	1160
2023 Q3	$264K	Buy	+27,100	New	+$321K	0.02%	741
2023 Q2	–	Sell	-26,000	Closed	-$281K	–	1162
2023 Q1	$281K	Buy	+26,000	New	+$333K	0.02%	673

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Prelude Capital Management's COGT Position: Q2 2026 in Review

Prelude Capital Management sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 64,222 shares — an estimated $2.47M sold.

Prelude Capital Management first reported a position in COGT in Q1 2023 and held it in 7 quarters. The position peaked at $2.57M in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Prelude Capital Management reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 64,222 Cogent Biosciences shares in Q2 2026, an estimated $2.47M.
Prelude Capital Management first reported a position in Cogent Biosciences in Q1 2023 and held it in 7 quarters.
Prelude Capital Management's Cogent Biosciences position peaked at $2.57M in Q4 2025.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.